This retrospective cohort study identifies strong associations between Hallucinogen Persisting Perception Disorder (HPPD) and pre-existing anxiety, functional somatic syndromes, and psychiatric comorbidities, highlighting the need for comprehensive clinical assessment in patients presenting with visual disturbances.

This article addresses the clinical phenomenon of tolerance to stimulant medications in children with ADHD, offering insights relevant to prescribing strategies for managing long-term efficacy.

The American Medical Association provides a comprehensive clinical guide for the safe and effective prescribing of psychotropic medications.

Fluorine-modified antisense oligonucleotides effectively target C9ORF72 repeat RNA to reduce toxicity in frontotemporal dementia and ALS, offering a potential therapeutic strategy for these neurodegenerative conditions.

The FDA has granted fast-track status to psilocybin and methylone, signaling regulatory progress for these psychedelics in psychiatric treatment development.

PBPK modeling offers a critical tool for optimizing antidepressant dosing in pregnancy to account for physiological changes, though its direct clinical utility remains an emerging area of practice.

This study identifies a frontotemporal dementia-like phenotype in schizophrenia linked to striatal dopamine and iron accumulation, offering mechanistic insights for targeting neurodegenerative pathways in psychosis.

This study identifies connexin 36 as a critical regulator of thalamocortical synchrony and proposes it as a novel therapeutic target for modulating network dysfunction in schizophrenia.

This study elucidates the molecular mechanisms behind the entourage effect of psilocybin-producing mushrooms, offering critical insights into their pharmacodynamics as a potential psychiatric treatment.

Elevated glutamine levels, distinct from glutamate, are identified as a potential biomarker for clozapine eligibility in early psychosis patients.

This study identifies engagement of the right frontal pole as a key neural correlate predicting antidepressant response to Transcranial Magnetic Stimulation (TMS).

A nationwide study reveals that only 40.2% of pregnant women with opioid use disorder receive medication for OUD, highlighting significant gaps in evidence-based prescribing despite MOUD being the gold standard.

The FDA is accelerating development and review timelines for psychedelic therapies targeting depression, PTSD, and alcohol use disorder through priority vouchers and IND clearances while preparing specific guidance to address prior methodological gaps in trial design.

Three companies received FDA priority review vouchers for their psychedelic drug candidates, signaling a potential shift in regulatory support under the current administration.

The FDA has granted priority review vouchers to three companies for psychedelic treatments targeting treatment-resistant depression and PTSD, signaling accelerated regulatory pathways for these emerging psychotropics.

The FDA has awarded three fast-track vouchers to unspecified psychedelic companies, signaling regulatory support for drug development in this therapeutic area.

The FDA has awarded Priority Review Vouchers to Otsuka, Compass, and Usona for their psychedelic drug candidates, a regulatory milestone that accelerates the review timeline for these potential psychiatric treatments.

First responders with PTSD are participating in a psilocybin clinical trial in Arizona, representing a potential new treatment avenue for this high-risk occupational group.

First responders with PTSD are participating in a clinical trial of psilocybin in Arizona, representing a potential new treatment avenue for this high-risk population.

First responders with PTSD are participating in a clinical trial investigating the efficacy of psilocybin for treating post-traumatic stress disorder.

A randomized trial is evaluating intranasal dexmedetomidine as a potential treatment for acute anxiety states in adults.

Real-world data from a large-scale study evaluates the clinical outcomes of intravenous racemic ketamine infusions for major depressive disorder and bipolar disorder.

This podcast discusses the emerging off-label use of GLP-1 agonists in psychiatry for managing antipsychotic-induced weight gain, cognitive impairment, and mood disorders, highlighting their potential to treat conditions like anhedonia and alcohol use disorder.

This fMRI study identifies specific disruptions in the functional connectivity of anterior insula subregions within the threat network in PTSD, highlighting distinct hemispheric patterns that may inform future neuromodulation targets.